Replies to post #789086 on NorthWest Biotherapeutics Inc (NWBO)

[Hopeforthefuture3]

Bas, if dcvax is to be made at thousands of locations as you posted how will they accomplish the stringent qa/qc for each batch which management has said is required. I see it as centralized manufacturing for quite some time

[exwannabe]

If a franchise model is implemented, which most likely will, then the franchisees are those that produce DCVax. With its decentralized mfg model, with the Eden device, that can include 1000s of hospitals and clinics worldwide.

The "Franchise Model" for marketing DC-L is a constuct of tis message board and bakes little sence.

The statement by LP that triggered the talk was at the 2023 ASM (held June 24).

Our goal is to build a franchise in dendritic cell technologies. We want to build a leading, and preferably THE leading franchise in this area.

In this context, the word franchise refers to a core product one can build around, Merck popularized the phrase for biotechs when it referred to Keytruda as their "franchise".

Contracting a company to perform sales and marketing is possible, but that is not a franchise model.

[SkyLimit2022]

EDEN & expanding standardized manufacturing capacity is a 🔑 key component of NWBO’s prospective business model for sure!

Aside from automated manufacturing, the most exciting & relevant topic is COMBO agents!

⭐️ PD1
⭐️ TLR
⭐️ STING
⭐️ CD40

PD1 & TLR are relatively recent as combos & have reached PII in combo with DC platforms. I can’t wait to see what comes next…



10-Q Quarterly Report

10-K Annual Report